A Phase I Study of Autologous CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Relapsed and Refractory B-cell Leukaemia and Lymphoma (The Auto-CAR19 Trial).

自体 CD19 特异性嵌合抗原受体 T 细胞治疗复发性和难治性 B 细胞白血病和淋巴瘤的 I 期研究（Auto-CAR19 试验）。

• 批准号: nhmrc : 1121704
• 负责人: A/Pr Tracey O'Brien
• 金额: $ 39.87万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/phase-i-study-car19-trial/946792
• 关键词: Phase; Study; Autologous; CD19; Specific

Most people with leukaemia and lymphoma who relapse early after chemotherapy die of their disease. Inserting special genes into immune cells can enable them to kill leukaemia and lymphoma and has led to dramatic cures, but the cost of the viral vectors used to make these cells is prohibitively expensive. We will make leukaemia and lymphoma specific immune cells from patients using an inexpensive non-viral system, then administer the immune cells to patients to assess their safety and efficacy.

大多数白血病和淋巴瘤患者在化疗后早期复发后死于疾病。将特殊基因插入免疫细胞可以使它们杀死白血病和淋巴瘤，并导致戏剧性的治疗，但用于制造这些细胞的病毒载体的成本非常昂贵。我们将使用一种廉价的非病毒系统从患者身上制造白血病和淋巴瘤特异性免疫细胞，然后将免疫细胞给予患者，以评估其安全性和有效性。